NCT01542242View on ClinicalTrials.gov

Liraglutide Use in Prader-Willi Syndrome

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Diabetes Mellitus Type 2Prader Willi Syndrome
Interventions
DRUG

Liraglutide

Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.

Trial Locations (1)

V5Z 1M9

Vancouver General Hospital - Diamond Center, Vancouver

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Vancouver General Hospital

OTHER

NCT01542242 - Liraglutide Use in Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter